Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions

Area of Science:

• Oncology
• Dermatology
• Genetics

Background:

• Melanocytic lesions encompass benign nevi, Spitz nevi, and melanoma.
• Activating mutations in RAS-RAF oncogenes drive cellular proliferation via the MAP kinase pathway.
• Understanding these mutations is crucial for diagnosing and treating skin cancers.

Purpose of the Study:

• To analyze activating mutations in NRAS, HRAS, and BRAF oncogenes in Spitz nevi (SN), common benign nevi (CBN), and cutaneous metastatic melanoma (CMM).
• To investigate loss of heterozygosity (LOH) and microsatellite instability in SN.
• To screen for germline BRAF mutations in melanoma families.

Main Methods:

• Genomic DNA analysis for HRAS, NRAS, and BRAF mutations.
• Loss of heterozygosity (LOH) analysis at 9p and 10q regions.
• Microsatellite instability analysis.
• Germline DNA screening in melanoma families.

Main Results:

• HRAS G61L mutation found in 4.5% of SN; BRAF V600E in one 'halo' SN.
• BRAF V600E mutations detected in two-thirds of CBN; NRAS mutations in 19%.
• One-third of CMM had BRAF mutations; 6% had NRAS mutations.
• SN showed LOH at 9p loci and microsatellite instability at one locus.
• No germline BRAF mutations found in melanoma families.

Conclusions:

• The low frequency of RAS-RAF mutations in SN suggests alternative activating mutations in the MAP kinase pathway.
• Distinct mutation profiles exist across different melanocytic lesions.
• Further research is needed to identify novel mutations in SN.